Catheter Ablation compared with optimized Pharmacological Therapy for Atrial Fibrillation - CAPTAF

Aug 29, 2017
Font Size
A
A
A
Author/Summarized by Author:
Anthony A. Bavry, MD, MPH, FACC
Summary Reviewer:
Deepak L. Bhatt, MD, MPH, MBA, FACC
Trial Sponsor:
Swedish Research Council, Swedish Heart-Lung Foundation, Medtronic AB.
Date Presented:
08/29/2017
Original Posted Date:
08/29/2017
References

Contribution To Literature:

The CAPTAF trial showed improvement in quality of life with catheter ablation for atrial fibrillation.

Description:

The goal of the trial was to evaluate catheter ablation compared with pharmacological therapy among patients with paroxysmal or persistent atrial fibrillation.

Study Design

  • Randomized
  • Parallel

A total of 155 patients with paroxysmal or persistent atrial fibrillation who failed at least one antiarrhythmic drug were randomized to catheter ablation versus optimized pharmacological therapy.

Inclusion criteria:

  • Patients with paroxysmal or persistent atrial fibrillation who failed at least one antiarrhythmic drug

Principal Findings:

The primary outcome, general health score at 12 months, improved significantly more in the ablation group (mean change = 11) than in the drug group (mean change = 3.1) (p = 0.0084).

There was no reduction in atrial fibrillation burden with catheter ablation versus pharmacological therapy.

Interpretation:

Among patients with paroxysmal or persistent atrial fibrillation who had failed at least one antiarrhythmic drug, catheter ablation was associated with improvement in quality of life compared with optimized drug therapy.

References:

Presented by Dr. Carina Blomstrom-Lundqvist at the European Society of Cardiology Congress, Barcelona, Spain, August 29, 2017.

Keywords: Anti-Arrhythmia Agents, Arrhythmias, Cardiac, Atrial Fibrillation, Catheter Ablation, Drug Therapy, ESC Congress, ESC2017, Quality of Life, Primary Prevention


< Back to Listings